VRAX
Q4 2026 EPS Estimate
$-1.75
Dec 2, 2026
Revenue Estimate
$12,423

Analyst Sentiment

Wall St. Consensus
Buy
1 analyst·Low coverage
75
Score
1 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$1.00
-64.5%
Consensus
$1.00
-64.5%
Bull
$1.00
-64.5%
12-Month Target Range1 analyst
$1.00$1.00$1.00
Current $2.82Consensus
Current Price
$2.82
Above Consensus
$1.82

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-90.00%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2027E
Revenue Avg$4,000
Low$4,000
High$4,000
EBITDA Avg$-2M
Low$-2M
High$-2M
EBIT Avg$-2M
Low$-2M
High$-2M
Net Income Avg$-2M
Low$-2M
High$-2M
EPS Avg$-6.00
Low$-6.00
High$-6.00
Analysts (Rev / EPS)1 / 1
Quarterly
MetricQ3 2026
Revenue Avg$13,893
Low$13,893
High$13,893
EBITDA Avg$-310,276
Low$-310,276
High$-310,276
EBIT Avg$-654,000
Low$-654,000
High$-654,000
Net Income Avg$-695,784
Low$-695,784
High$-695,784
EPS Avg$-1.75
Low$-1.75
High$-1.75
Analysts (Rev / EPS)1 / 1

Earnings Surprises

Recent Analyst Actions

Jan 9, 2026H.C. Wainwright
Virax Biolabs price target lowered to $1 from $3 at H.C. Wainwright
Target:$1.00
+165.8%from $0.38
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.